WARRINGTON, PA — Windtree Therapeutics, Inc. announced a bold new plan to establish itself as a revenue-generating biotechnology company by acquiring small businesses with FDA-approved products. At the same time, the company remains committed to advancing its pipeline of innovative therapies for critical conditions in cardiovascular and oncology fields.
The company’s strategy focuses on acquiring small biotech firms that struggle to maximize the commercialization potential of their FDA-approved products. By becoming a parent company to these smaller entities, Windtree aims to create a robust portfolio of subsidiaries, driving revenue through strategic, synergistic efforts.
Windtree’s leadership brings extensive experience in both large pharmaceutical operations and smaller biotech ventures. With expertise across multiple therapeutic areas, the management team is well-positioned to optimize the commercial performance of its potential acquisitions.
According to CEO Jed Latkin, this transition represents a significant opportunity for growth. “We believe that Windtree becoming a revenue-generating company would be a significantly positive transformation and would mark a new chapter in our growth story,” said Latkin. He emphasized that the approach balances the company’s commitment to advancing its development pipeline with creating near-term value through commercial operations.
The company plans to leverage equity for these acquisitions, targeting businesses whose products show strong market potential. While the number of deals will depend on valuation and growth opportunities, the overall strategy positions Windtree to capitalize on unmet market needs.
Through this dual focus on strategic acquisitions and groundbreaking therapies, Windtree Therapeutics aims to build a strong foundation for sustained revenue growth, marking an exciting new phase in its evolution.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.